Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 2.268
Filtrar
1.
PLoS One ; 15(8): e0237338, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32797093

RESUMEN

OBJECTIVE: The study was aimed to explore patient safety culture of community pharmacists working in Dessie and Gondar towns, Northern Ethiopia. METHODS: A cross-sectional study was conducted from 1st to 31st March 2018. In this cross-sectional survey, the Pharmacy Survey on Patient Safety Culture (PSOPSC), developed by the Agency for Healthcare Research and Quality (AHRQ), was used to collect data. PSOPSC is a self-administered questionnaire. The questionnaire was distributed among staffs who work in community pharmacies of Dessie and Gondar towns. All staffs available on data collection period in the pharmacy were included. The Statistical Package for Social Science (SPSS) software version 25 was used to enter and analyze the data. RESULTS: A total of 120 participants were approached and completed the questionnaire. Results from the study showed that high positive response rate was demonstrated in the domains of "Teamwork" (90.2%) followed by physical space and environment (83.1%). On the other hand, the result also identified that there is an enormous problem related to mistake communication (44.8%) and work pressure (45%). In addition, significant difference of percent positive responses were obtained across towns and staff working hours. CONCLUSIONS: The patient safety culture of community pharmacists is appreciable especially with respect to their teamwork. Besides, urgent attention should be given to areas of weakness, mainly in the domain of "mistake communication" and "staffing and work pressure".


Asunto(s)
Servicios Comunitarios de Farmacia/organización & administración , Seguridad del Paciente , Farmacéuticos/organización & administración , Administración de la Seguridad/estadística & datos numéricos , Adulto , Servicios Comunitarios de Farmacia/estadística & datos numéricos , Estudios Transversales , Etiopía , Femenino , Humanos , Relaciones Interprofesionales , Masculino , Persona de Mediana Edad , Admisión y Programación de Personal/organización & administración , Admisión y Programación de Personal/estadística & datos numéricos , Farmacéuticos/psicología , Farmacéuticos/estadística & datos numéricos , Encuestas y Cuestionarios/estadística & datos numéricos , Carga de Trabajo/psicología , Carga de Trabajo/estadística & datos numéricos , Adulto Joven
2.
Prev Chronic Dis ; 17: E74, 2020 07 30.
Artículo en Inglés | MEDLINE | ID: mdl-32730199

RESUMEN

Medically underserved patients in rural areas are more vulnerable to poor health outcomes, including the risks associated with coronavirus disease 2019 (COVID-19). Pharmacists, student pharmacists, and other health care professionals are working together to implement new, innovative ways to deliver the same standard of care during the COVID-19 pandemic to these vulnerable patients. These services include telehealth with virtual and telephone medication therapy management sessions led by ambulatory care pharmacists and student pharmacists. Pharmacists, student pharmacists, and other health care professionals should continue to adapt to these new technologies to improve health outcomes for their patients during the pandemic.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/prevención & control , Área sin Atención Médica , Pandemias/prevención & control , Farmacéuticos/organización & administración , Neumonía Viral/epidemiología , Neumonía Viral/prevención & control , Población Rural , Enfermedad Crónica , Servicios Comunitarios de Farmacia , Florida , Humanos , Administración del Tratamiento Farmacológico/organización & administración , Rol Profesional , Telemedicina
4.
Ann Hematol ; 99(7): 1615-1625, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32483668

RESUMEN

Ibrutinib treatment has been shown to increase survival in patients with B cell malignancies. Real-life data suggest a large part of discontinuations are due to toxicities, impairing ibrutinib efficacy. We aimed to assess the impact of a pharmaceutical care program on the efficacy and safety of ibrutinib. This single-center, cohort, observational study enrolled patients with B cell malignancies. Patients were either assigned to the program or to receive usual care, based on physician decision. The program was conducted by clinical pharmacists specializing in oncology and included patient education for management of toxicities, adherence monitoring, interventions to reduce drug-drug interactions, and follow-up of transition from hospital to community. Between February 2014 and May 2017, we enrolled 155 patients, including 42 (27%) who were allocated to the program group and 113 (73%) to the usual care group. The effect of the program was beneficial in terms of time to treatment failure (p = 0.0005). The 30-month progression-free and overall survivals were significantly superior in the program group (respectively p = 0.002 and p = 0.004). Grade 3 or higher adverse events occurred more frequently for patients in the usual care group (15%) than program group (8%). A pharmaceutical care program provides a personalized environment for outpatient monitoring and control of the key risks associated with oral anticancer agents. This study shows evidence that management of ibrutinib treatment by clinical pharmacists results in significant improvement in survival and better tolerance than usual care.


Asunto(s)
Neoplasias/tratamiento farmacológico , Neoplasias/mortalidad , Servicios Farmacéuticos/normas , Pirazoles/uso terapéutico , Pirimidinas/uso terapéutico , Mejoramiento de la Calidad , Tiempo de Tratamiento/normas , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Eficiencia Organizacional , Femenino , Humanos , Masculino , Persona de Mediana Edad , Servicios Farmacéuticos/organización & administración , Servicios Farmacéuticos/tendencias , Farmacéuticos/organización & administración , Farmacéuticos/normas , Análisis de Supervivencia , Factores de Tiempo , Tiempo de Tratamiento/organización & administración , Tiempo de Tratamiento/tendencias , Insuficiencia del Tratamiento
5.
Int J Clin Pharm ; 42(4): 1197-1206, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32524513

RESUMEN

Background An infectious disease caused by a novel coronavirus (later called COVID-19) reached pandemic levels in 2020 and community pharmacists were involved in responding to this pandemic, also in Kosovo. Objectives To explore the experiences of community pharmacists in relation to provision of community pharmacy services during COVID-19 pandemic. Setting Community pharmacists in Kosovo. Methods This was a cross-sectional study where data was collected via a self-administered online questionnaire, from 264 pharmacists actively practicing in Kosovo during the pandemic. The questionnaire consisted of a combination of closed and open-ended questions, optional statements and statements on a five-point Likert scale, derived at least in part from the Transtheoretical Model. One-way analysis of variance was used to analyze differences in responses to Likert-type items whereas categorical variables were analyzed using Chi square testing. Main outcome measures Community pharmacists' perceptions on COVID-19 related preventative measures. Results A response rate of 40.6% was achieved. Sufficient and adequate COVID-19-related preventative measures were being implemented by a majority of pharmacies (n = 232; 87.9%), and over two-thirds of respondents agreed/strongly agreed that their pharmacies were sufficiently prepared with protective equipment for their personnel. Implementation of preventative measures was associated with respondents' perception that pharmacists and the pharmacy profession were valued more by patients during the pandemic and to a lesser degree, by other health professionals. Most commonly stated pros dealt with employee and patient safety, while key cons dealt with increased costs and running out of the necessary protective equipment. Key barriers to pharmacy activities were price increases by wholesalers, and patients' panic and excessive buying, whereas drivers dealt with professional obligation to assist and opportunity to prove inseparable to other health professionals. The most popular means of accessing COVID-19 related information by pharmacists was via mobile devices and information from professional organizations was considered most useful by pharmacists. Conclusions Community pharmacies actively implemented various measures as precautions to mitigate the spread of COVID-19. Our findings highlight the value of continuous provision of information by professional organizations and use of mobile devices as key means to access information by pharmacists.


Asunto(s)
Servicios Comunitarios de Farmacia/organización & administración , Infecciones por Coronavirus/prevención & control , Pandemias/prevención & control , Farmacéuticos/organización & administración , Neumonía Viral/prevención & control , Teléfono Celular/estadística & datos numéricos , Infecciones por Coronavirus/epidemiología , Estudios Transversales , Femenino , Humanos , Kosovo , Masculino , Neumonía Viral/epidemiología , Rol Profesional , Sociedades Farmacéuticas/estadística & datos numéricos , Encuestas y Cuestionarios
8.
Rev Med Suisse ; 16(697): 1210-1213, 2020 Jun 10.
Artículo en Francés | MEDLINE | ID: mdl-32520461

RESUMEN

Polypharmacy is common in patients with a chronic disease. It is appropriate when both the patient and the physician discuss the goal of each prescribed medication with a motivated patient capable of managing his/her medication. It can however be inappropriate when treatment becomes too complex for the frail patient. The risk is non-adherence to therapy, which often results in an intensification of treatment due to unmet therapeutic goals. Collaboration between physicians and pharmacists is therefore essential for the educational support of patients with polypharmacy. In this article, we review the studies examining the impact of a physician-pharmacist collaboration on the medication adherence of diabetic patients with renal impairment.


Asunto(s)
Nefropatías Diabéticas/tratamiento farmacológico , Nefropatías Diabéticas/psicología , Cumplimiento de la Medicación , Farmacéuticos/organización & administración , Médicos/organización & administración , Humanos , Polifarmacia
11.
Int J Clin Pharm ; 42(5): 1379-1384, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32472325

RESUMEN

The coronavirus disease 2019 (COVID-19) pandemic has greatly impacted healthcare services around the world. Pharmacists are front-line healthcare professionals and integral members of the healthcare team. The deployment of a specialized 'COVID pharmacist' within our institution has demonstrated that the skills of the pharmacist can be adapted, expanded and utilized to alleviate the pressure of doctor shortages, reduce healthcare worker exposure to infected patients, contribute to therapeutic decisions and work collaboratively to tackle the challenges faced during this pandemic. This commentary details an Australian hospital pharmacy response to the COVID-19 pandemic, describing the unique clinical and practical contributions made by a specialized COVID pharmacist in our institution.


Asunto(s)
Infecciones por Coronavirus/epidemiología , Grupo de Atención al Paciente/organización & administración , Farmacéuticos/organización & administración , Servicio de Farmacia en Hospital/organización & administración , Neumonía Viral/epidemiología , Australia , Competencia Clínica , Conducta Cooperativa , Prestación de Atención de Salud/organización & administración , Humanos , Pandemias , Rol Profesional
12.
Am J Health Syst Pharm ; 77(Supplement_2): S34-S40, 2020 May 19.
Artículo en Inglés | MEDLINE | ID: mdl-32426832

RESUMEN

PURPOSE: A survey was conducted to evaluate the characteristics and structures of postgraduate year 2 (PGY2) ambulatory care pharmacy residency programs in the United States. The survey results can serve as a guide for current and newly emerging programs. METHODS: A 24-question survey was sent to 138 US PGY2 residency program directors (RPDs) in February 2017 to identify key program characteristics, including program type (single-site or multisite), primary practice site, number of residents, length and type of rotations, staffing requirements, additional residency activities, precepting and teaching opportunities, RPD training and credentials, and number and qualifications of preceptors. Descriptive statistics were used to analyze the findings. RESULTS: A 40.6% response rate was achieved. Well over half (57%) of programs had been established within the preceding 5 years. A majority of RPDs reported that their program had 1 (53%) or 2 residents (31%) and/or was a single-site program (80%). Overall, 44 different types of rotations or experiences were offered by the programs. All surveyed programs offered additional teaching opportunities. There were no formal staffing duties in 29% of programs; professional organization membership and conference attendance were highly encouraged but typically not required of residents. Qualifications of the RPD and preceptors closely mirrored those delineated in residency accreditation standards. CONCLUSION: There is an increased need for specialized training in ambulatory care in order to prepare pharmacists for the changing landscape in healthcare. The profession is adapting to this need, as evidenced by the rapid growth of PGY2 ambulatory care residency programs. Understanding characteristics can benefit continued growth to meet the needs of the profession.


Asunto(s)
Instituciones de Atención Ambulatoria/organización & administración , Atención Ambulatoria/organización & administración , Servicios Farmacéuticos/organización & administración , Residencias en Farmacia/organización & administración , Acreditación , Humanos , Farmacéuticos/organización & administración , Preceptoría , Estudiantes de Farmacia , Encuestas y Cuestionarios , Estados Unidos
13.
Am J Health Syst Pharm ; 77(Supplement_2): S54-S58, 2020 May 19.
Artículo en Inglés | MEDLINE | ID: mdl-32426834

RESUMEN

PURPOSE: To streamline workflow of the culture review process in the emergency department (ED), a transition from a nurse-driven to a pharmacist-initiated process was implemented. METHODS: This was a single-center retrospective study conducted at an adult urban level 1 trauma academic medical center. The pharmacist-initiated culture review process was compared to the previous nurse-initiated process. The primary objective was time from final culture result to patient contact by an advanced practice provider. Secondary objectives included incidence of treatment failure and hospital admission within 30 days of ED visit. RESULTS: A total of 283 patients met inclusion criteria: 144 patients in the pre-intervention group and 139 patients in the postintervention group. Patients were contacted a median time of 15.7 hours (95% confidence interval [CI], 9.88-18.83) earlier for definitive urinary tract infection antibiotic therapy and 46.7 hours (95% CI, 33.34-61.62) earlier for definitive sexually transmitted infection therapy in the pharmacist-initiated workflow compared to the nurse-initiated workflow (P < 0.001). Treatment failure occurred in 0.01% of patients in the postintervention group and 6.3% in the pre-intervention group (P = 0.01). Hospital admission within 30 days of the ED visit occurred in 0% of patients in the postintervention group and 4.2% in the pre-intervention group (P = 0.03). CONCLUSION: Pharmacist-initiated culture review in the ED at an academic medical center reduced time from final culture to patient contact for optimal antibiotic therapy and decreased hospital admission and treatment failure rates. A change in the culture review workflow involving pharmacists appears to have a positive impact on clinical outcomes.


Asunto(s)
Servicio de Urgencia en Hospital , Farmacéuticos/organización & administración , Enfermedades de Transmisión Sexual/tratamiento farmacológico , Infecciones Urinarias/tratamiento farmacológico , Centros Médicos Académicos , Adolescente , Adulto , Antibacterianos/administración & dosificación , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Masculino , Persona de Mediana Edad , Servicio de Farmacia en Hospital/organización & administración , Rol Profesional , Estudios Retrospectivos , Enfermedades de Transmisión Sexual/diagnóstico , Factores de Tiempo , Insuficiencia del Tratamiento , Infecciones Urinarias/diagnóstico , Adulto Joven
14.
J Am Pharm Assoc (2003) ; 60(3): 431-438.e1, 2020.
Artículo en Inglés | MEDLINE | ID: covidwho-47500

RESUMEN

OBJECTIVES: To describe the pharmacy administration and pharmaceutical care in a module hospital during the coronavirus disease 2019 (COVID-19) epidemic and provide reference for domestic and foreign pharmacists participating in the epidemic prevention and control. SETTING: The study was performed in a Jianghan module hospital constructed at the Wuhan Convention and Exhibition Center in Wuhan, China. This is 1 of the first 3 module hospitals. PRACTICE DESCRIPTION: One thousand eight hundred forty-eight patients were admitted to the Jianghan module hospital, and 1327 cases (71.81% of the total number) were cured and discharged. Pharmacists have successfully completed the tasks of purchase, storage, and free distribution of drugs worth ¥1.03 million (approximately $146,000), reviewed about 20,000 electronic orders, provided one-on-one online medication consultation for 484 patients, and held 5 lectures on rational drug use knowledge, which could help reduce irrational drug use and minimize the risk involved. PRACTICE INNOVATION: The new COVID-19 "module" pharmaceutical care model is equipped with new features such as pharmacy emergency command group, organizational structure for pharmacy administration, electronic control of drug prescription, and "zero contact" pharmaceutical care relying on the new media platform "WeChat." This platform provides relevant pharmaceutical care for patients, such as ensuring drug supply, setting up critical care drug trolleys, designing specific drug packaging bags, creating a module radio station to broadcast rational drug use information to the patients, and other aspects. EVALUATION: With the continuous improvement of the module hospital and the progress in in-depth knowledge about COVID-19, some aspects such as patient admission criteria and variety of drugs need to be adjusted depending on the actual situation. RESULTS: The pharmacists provided pharmaceutical care for 1848 patients with mild COVID-19 disease. They not only ensured the timely supply of the drugs but also reduced the incidence of drug-induced risks through medication review and guidance, thereby improving patient compliance and helping the patients rebuild their confidence in overcoming the disease. CONCLUSION: The new COVID-19 module pharmaceutical care model has played an important role in overcoming the epidemic situation of COVID-19 in China and thus can be implemented on a broader scale.


Asunto(s)
Infecciones por Coronavirus/tratamiento farmacológico , Hospitales Especializados/organización & administración , Farmacéuticos/organización & administración , Servicio de Farmacia en Hospital/organización & administración , Neumonía Viral/tratamiento farmacológico , Adolescente , Adulto , Anciano , China/epidemiología , Infecciones por Coronavirus/epidemiología , Hospitalización , Humanos , Masculino , Persona de Mediana Edad , Pandemias , Administración Farmacéutica , Neumonía Viral/epidemiología , Rol Profesional , Adulto Joven
15.
Public Health Rep ; 135(3): 313-321, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32228133

RESUMEN

OBJECTIVES: Despite the safety and efficacy of the human papillomavirus (HPV) vaccine, many persons are still not receiving it. The purpose of this pilot project was to evaluate the number of first doses of the 9-valent HPV (9vHPV) vaccination administered after a pharmacist-led intervention in the Adult Family Planning Clinic at Grady Health System (GHS), a large academic urban medical center in Atlanta, Georgia. METHODS: The pilot project had 3 phases: pre-intervention (November 15, 2016, through March 31, 2017), active intervention (November 15, 2017, through December 29, 2017), and post-intervention (December 30, 2017, through March 31, 2018). The pre-intervention phase was used as a historical control. The active intervention phase consisted of pharmacist interventions in the clinic and patient and health care provider education. The post-intervention phase evaluated the durability of pharmacist-led interventions performed and education provided during the active phase. RESULTS: Eighty-nine first-dose 9vHPV vaccines (of the 3-dose series) were administered to young adults aged 18-26 during the project period (November 15, 2017, through March 31, 2018); none were administered during the pre-intervention phase. Of 89 patients who received a first 9vHPV vaccine dose, 20 patients also received a second 9vHPV vaccine dose. During the project period, 166 doses of 9vHPV vaccine (first, second, or third doses) were administered. CONCLUSION: This pharmacist-led intervention led to an increase in the number of young adult patients receiving their first dose of the 9vHPV vaccination series. With the support of other health care providers, pharmacist-led initiatives can expand vaccine-related health literacy and facilitate access to immunization services.


Asunto(s)
Promoción de la Salud/organización & administración , Infecciones por Papillomavirus/prevención & control , Vacunas contra Papillomavirus/administración & dosificación , Farmacéuticos/organización & administración , Centros Médicos Académicos/organización & administración , Adolescente , Adulto , Femenino , Humanos , Masculino , Servicio Ambulatorio en Hospital/organización & administración , Proyectos Piloto , Rol Profesional , Neoplasias del Cuello Uterino/prevención & control , Adulto Joven
16.
J Oncol Pharm Pract ; 26(5): 1172-1179, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32299314

RESUMEN

OBJECTIVES: To evaluate clinical and financial impact of pharmacist interventions in an ambulatory adult hematology-oncology department. METHODS: All cancer patients receiving a first injectable immuno- and/or chemotherapy regimen were included in this prospective study over a one-year period. The clinical impact of pharmacist interventions made by two clinical pharmacists was rated using the Clinical Economic and Organizational tool. Financial impact was calculated through cost savings and cost avoidance. Main results: Five hundred and fifty-eight patients were included. A total of 1970 pharmacist interventions were performed corresponding to a mean number of 3.5 pharmacist interventions/patient. The clinical impact of pharmacist interventions was classified as negative, null, minor, moderate, major and lethal in 0, 84 (4%), 1353 (68%), 385 (20%), 148 (8%) and 0 cases, respectively. The overall cost savings were €175,563. One hundred and nine (6%) of all pharmacist interventions concerned immuno- or chemotherapy regimen for cost savings of €148,032 (84% of the total amount of cost savings). The cost avoidance was €390,480. Cost avoidance results were robust to sensitivity analyses with cost of preventable adverse drug event as main driver of the model. When the cost of employing a pharmacist was subtracted from the average yearly cost savings plus cost avoidance per pharmacist, this yielded a net benefit of €223,021. The cost-benefit ratio of the clinical pharmacist was €3.7 for every €1 invested. Principal conclusions: To have two full-time clinical pharmacists in a 55-bed ambulatory adult hematology-oncology department is both clinically and financially beneficial.


Asunto(s)
Neoplasias/tratamiento farmacológico , Farmacéuticos/organización & administración , Servicio de Farmacia en Hospital/economía , Anciano , Anciano de 80 o más Años , Instituciones de Atención Ambulatoria/organización & administración , Ahorro de Costo , Análisis Costo-Beneficio , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos
17.
J Oncol Pharm Pract ; 26(3_suppl): 33-39, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-32268830

RESUMEN

The International Society of Oncology Pharmacy Practitioners organized a workshop to create learning opportunities on biosimilars in pharmacy practice on 10 October 2019. The topics that were covered included (i) the development and testing of biosimilars, (ii) the challenges of bringing biosimilars to market, and (iii) real-world data on patient safety and perceptions during biosimilar implementation. The development of biosimilars can take up to eight years and the extensiveness of the process depends on several factors, such as the complexity of the production process and regulatory requirements. Compared to generic products of small-molecule drugs, there is a higher barrier to market entry for biosimilars, explaining the small number of biosimilars in the market. Appraisal of biosimilars for inclusion in hospital formularies is also different from the review process of originator biologics, where the former is usually institution-led and has fewer restrictions on use. When several biosimilar products are available, factors that should be considered besides cost are licensed indications, supply chain confidence, clinical data, and product attributes. Real-world data have shown that biosimilars are well-tolerated and have safety data that are comparable to that of the originator product. Oncology pharmacists from the United Kingdom, Kenya, and Canada also presented their respective experiences with biosimilar use. Different countries at varying stages of biosimilar implementation faced distinct challenges. Nevertheless, resources to assist biosimilar implementation can potentially be shared between different regions. International Society of Oncology Pharmacy Practitioners is well-positioned to foster professional cooperation at an international level to drive biosimilar implementation.


Asunto(s)
Biosimilares Farmacéuticos/administración & dosificación , Servicios Farmacéuticos/organización & administración , Farmacéuticos/organización & administración , Humanos , Neoplasias/tratamiento farmacológico
18.
J Am Pharm Assoc (2003) ; 60(3): 431-438.e1, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32336673

RESUMEN

OBJECTIVES: To describe the pharmacy administration and pharmaceutical care in a module hospital during the coronavirus disease 2019 (COVID-19) epidemic and provide reference for domestic and foreign pharmacists participating in the epidemic prevention and control. SETTING: The study was performed in a Jianghan module hospital constructed at the Wuhan Convention and Exhibition Center in Wuhan, China. This is 1 of the first 3 module hospitals. PRACTICE DESCRIPTION: One thousand eight hundred forty-eight patients were admitted to the Jianghan module hospital, and 1327 cases (71.81% of the total number) were cured and discharged. Pharmacists have successfully completed the tasks of purchase, storage, and free distribution of drugs worth ¥1.03 million (approximately $146,000), reviewed about 20,000 electronic orders, provided one-on-one online medication consultation for 484 patients, and held 5 lectures on rational drug use knowledge, which could help reduce irrational drug use and minimize the risk involved. PRACTICE INNOVATION: The new COVID-19 "module" pharmaceutical care model is equipped with new features such as pharmacy emergency command group, organizational structure for pharmacy administration, electronic control of drug prescription, and "zero contact" pharmaceutical care relying on the new media platform "WeChat." This platform provides relevant pharmaceutical care for patients, such as ensuring drug supply, setting up critical care drug trolleys, designing specific drug packaging bags, creating a module radio station to broadcast rational drug use information to the patients, and other aspects. EVALUATION: With the continuous improvement of the module hospital and the progress in in-depth knowledge about COVID-19, some aspects such as patient admission criteria and variety of drugs need to be adjusted depending on the actual situation. RESULTS: The pharmacists provided pharmaceutical care for 1848 patients with mild COVID-19 disease. They not only ensured the timely supply of the drugs but also reduced the incidence of drug-induced risks through medication review and guidance, thereby improving patient compliance and helping the patients rebuild their confidence in overcoming the disease. CONCLUSION: The new COVID-19 module pharmaceutical care model has played an important role in overcoming the epidemic situation of COVID-19 in China and thus can be implemented on a broader scale.


Asunto(s)
Infecciones por Coronavirus/tratamiento farmacológico , Hospitales Especializados/organización & administración , Farmacéuticos/organización & administración , Servicio de Farmacia en Hospital/organización & administración , Neumonía Viral/tratamiento farmacológico , Adolescente , Adulto , Anciano , China/epidemiología , Infecciones por Coronavirus/epidemiología , Hospitalización , Humanos , Masculino , Persona de Mediana Edad , Pandemias , Administración Farmacéutica , Neumonía Viral/epidemiología , Rol Profesional , Adulto Joven
20.
Postgrad Med ; 132(5): 426-432, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32207352

RESUMEN

Despite therapeutic advances, patients with acute coronary syndrome (ACS) are at an increased long-term risk of recurrent cardiovascular events. This risk continues to rise as the number of associated comorbidities, often observed in patients presenting with ACS, increases. Such a level of clinical complexity can lead to gaps in care and subsequently worse outcomes. Guidelines recommend providing an evidence-based post-discharge plan to prevent readmission and recurrent ACS, including cardiac rehabilitation, medication, patient/caregiver education, and ongoing follow-up. A patient-centric multidisciplinary approach is critical for the effective management of the transition of care from acute care in the hospital setting to the outpatient care setting in patients with ACS. Ongoing communication between in-hospital and outpatient healthcare providers ensures that the transition is smooth. Primary care providers and pharmacists have a pivotal role to play in the effective management of transitions of care in patients with ACS. Guideline recommendations regarding the post-discharge care of patients with ACS and the role of the primary care provider and the pharmacist in the management of transitions of care will be reviewed.


Asunto(s)
Síndrome Coronario Agudo/terapia , Continuidad de la Atención al Paciente/organización & administración , Farmacéuticos/organización & administración , Atención Primaria de Salud/organización & administración , Rol Profesional , Rehabilitación Cardiaca/métodos , Fármacos Cardiovasculares/uso terapéutico , Comunicación , Comorbilidad , Continuidad de la Atención al Paciente/normas , Femenino , Humanos , Masculino , Cumplimiento de la Medicación , Grupo de Atención al Paciente/organización & administración , Alta del Paciente/normas , Educación del Paciente como Asunto/organización & administración , Guías de Práctica Clínica como Asunto , Recurrencia , Factores de Riesgo , Factores Socioeconómicos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA